
    
      Participants will receive baseline testing to confirm a diagnosis of Parkinson's Disease and
      to determine eligibility in the research study. All of the participants in this study will
      receive the study drug (Exenatide). The study drug will be provided at the end of the first
      visit, and participants will be administered the drug once per week for the duration of the
      study (1 year).

      During the research study the following test may occur: (1) questionnaires about quality of
      life and depression; (2) tests to measure strength and motor function; (3) tests to measure
      cognition; (4) orientation session to learn a precision gripping task; (5) functional MRI
      scan of the brain; (6) structural MRI scan of the brain.
    
  